IL13 and asthma: Therefore, the anti-IgE omalizumab, the anti-IL-4/IL-13 dupilumab, and the anti-TSLP tezepelumab are supposed to have the ability to directly modulate the ASM contractility and AHR in asthma, by specifically blocking the interaction between the ligands and FcεRI, IL-4Rα, and TSLPR respectively, and indirectly by targeting eosinophils and further inflammatory cells, thus leading to a reduction in the inflammatory cascade.